Cargando…

Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy

[Image: see text] Adoptive cellular therapy utilizing chimeric antigen receptor redirected T (CAR-T) cells has shown impressive therapeutic effects on hematological malignancies. In contrast, the efficacy of CAR-T therapies in treating solid tumors is still poor, which is largely due to inefficient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yangyang, Dong, Yansong, Yang, Shuhan, Tu, Yalan, Wang, Chengbo, Li, Jun, Yuan, Youyong, Lian, Zhexiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136969/ https://www.ncbi.nlm.nih.gov/pubmed/35647274 http://dx.doi.org/10.1021/acscentsci.2c00163

Ejemplares similares

Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis
por: Zeglis, Brian M, et al.
Publicado: (2014)

Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
por: Yang, Fan, et al.
Publicado: (2023)

Hyaluronidase hypersensitivity: A rare complication of peribulbar block
por: Rajalakshmi, A R, et al.
Publicado: (2016)

Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
por: Sloas, Christopher, et al.
Publicado: (2021)

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T
por: Liu, Qiaofei, et al.
Publicado: (2023)

Recent Advances in CAR-Based Solid Tumor Immunotherapy
por: Shin, Min Hwa, et al.
Publicado: (2023)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors
por: Miao, Lele, et al.
Publicado: (2021)

Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
por: Yu, Tao, et al.
Publicado: (2022)

Comment on the Evaluation of the Effectiveness of Hyaluronidase in the Selective Nerve Root Block of Radiculopathy
por: Manchikanti, Laxmaiah, et al.
Publicado: (2015)

Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
por: Pesce, Silvia, et al.
Publicado: (2020)

THE INTERACTIONS OF THE NON-SPECIFIC INHIBITOR OF HYALURONIDASE WITH HYALURONIDASE AND PROTEOLYTIC ENZYMES IN VIVO
por: Hadidian, Z., et al.
Publicado: (1955)

CAR-Based Immunotherapy of Solid Tumours—A Survey of the Emerging Targets
por: Maher, John, et al.
Publicado: (2023)

The Future of Bioorthogonal Chemistry
por: Devaraj, Neal K.
Publicado: (2018)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

Hyaluronidases in Human Diseases
por: Kaul, Aditya, et al.
Publicado: (2021)

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer
por: Zhao, Ruocong, et al.
Publicado: (2021)

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
por: Arora, Sanjeevani, et al.
Publicado: (2019)

Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis
Publicado: (1979)

Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect
por: Chen, Enrui, et al.
Publicado: (2020)

The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors
por: Pensato, Umberto, et al.
Publicado: (2022)

A Bioorthogonal Quadricyclane Ligation
por: Sletten, Ellen M., et al.
Publicado: (2011)

Interfacial Bioorthogonal Cross-Linking
por: Zhang, Han, et al.
Publicado: (2014)

Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells
por: Ager, Ann, et al.
Publicado: (2016)

The Adrenal-Hyaluronidase Relationship in Infection
por: Smith, Geo. H., et al.
Publicado: (1951)

THE REACTIVATION OF HEAT-INACTIVATED HYALURONIDASE
por: Emmart, E. W., et al.
Publicado: (1954)

HYALURONIDASES OF BACTERIAL AND ANIMAL ORIGIN
por: Meyer, Karl, et al.
Publicado: (1941)

Involvement of hyaluronidases in colorectal cancer
por: Bouga, Helen, et al.
Publicado: (2010)

Hyaluronidase sensitivity: Our experience
por: Mayor, Rahul, et al.
Publicado: (2016)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Plasma hyaluronan, hyaluronidase activity and endogenous hyaluronidase inhibition in sepsis: an experimental and clinical cohort study
por: van der Heijden, Jaap, et al.
Publicado: (2021)

Isonitrile-responsive and bioorthogonally removable tetrazine protecting groups
por: Tu, Julian, et al.
Publicado: (2019)

CAR Based Immunotherapy of Solid Tumours—A Clinically Based Review of Target Antigens
por: Maher, John, et al.
Publicado: (2023)

Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation
por: Miller, Miles A., et al.
Publicado: (2018)

A narrative review: progress in transition metal-mediated bioorthogonal catalysis for the treatment of solid tumors
por: Wan, Xiaotian, et al.
Publicado: (2023)

Probing the Mycobacterial Trehalome with Bioorthogonal Chemistry
por: Swarts, Benjamin M., et al.
Publicado: (2012)

Development of Bioorthogonal Reactions and Their Applications in Bioconjugation
por: Zheng, Mengmeng, et al.
Publicado: (2015)

Bioorthogonal Ligations and Cleavages in Chemical Biology
por: Li, Youshan, et al.
Publicado: (2020)

Cell-specific bioorthogonal tagging of glycoproteins
por: Cioce, Anna, et al.
Publicado: (2022)

Nanozymes with bioorthogonal reaction for intelligence nanorobots
por: Sun, Si, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1nmnnrem1d8bhpnbdrmb4i70c7